Ildong Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Ildong Pharmaceutical has a total shareholder equity of ₩162.5B and total debt of ₩172.1B, which brings its debt-to-equity ratio to 105.9%. Its total assets and total liabilities are ₩590.5B and ₩427.9B respectively. Ildong Pharmaceutical's EBIT is ₩1.4B making its interest coverage ratio 0.1. It has cash and short-term investments of ₩61.4B.
Key information
105.9%
Debt to equity ratio
₩172.13b
Debt
| Interest coverage ratio | 0.1x |
| Cash | ₩61.42b |
| Equity | ₩162.55b |
| Total liabilities | ₩427.91b |
| Total assets | ₩590.46b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: A249420's short term assets (₩228.1B) do not cover its short term liabilities (₩279.0B).
Long Term Liabilities: A249420's short term assets (₩228.1B) exceed its long term liabilities (₩148.9B).
Debt to Equity History and Analysis
Debt Level: A249420's net debt to equity ratio (68.1%) is considered high.
Reducing Debt: A249420's debt to equity ratio has increased from 46.7% to 105.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable A249420 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: A249420 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 48.7% per year.